BCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain.
BCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain.
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
自 2018 年巴塞罗那临床肝癌预后和治疗策略最后一次正式更新以来，肝细胞癌（HCC）的治疗方法有了重大进展。虽然所有领域都有进展，但我们将重点介绍那些导致治疗策略发生变化的进展，并讨论为什么尽管令人鼓舞，但某些干预措施的数据仍然太不成熟，无法纳入临床医生和研究人员的循证模型。最后，我们描述了为个体患者做出临床决策所需的关键见解和专业知识，同时考虑了提供个性化临床管理所需考虑的所有参数。
